Menu
Recruiting NCT05845801

Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

Observational PDAC - Pancreatic Ductal Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Register.
Who it may be relevant to
Registry conditions: PDAC - Pancreatic Ductal Adenocarcinoma. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Interventions

  • Other Register
    Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Primary outcome measures

  • Register of young PDAC patients [Time frame: 30 years]

Eligibility criteria

Inclusion criteria

  • Age ≤55 years old at the time of diagnosis of pancreatic cancer
  • Age ≥ 18 years
  • Written informed consent obtained.

Exclusion criteria

  • Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor)
  • Absence of informed consent.
  • Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Italy · 1 center
  • AOUI Verona — Verona

Identifiers

NCT: NCT05845801 · 3968

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗